8CC Stock Overview
A biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cocrystal Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.04 |
| 52 Week High | US$2.54 |
| 52 Week Low | US$1.28 |
| Beta | 1.45 |
| 11 Month Change | 6.81% |
| 3 Month Change | 22.89% |
| 1 Year Change | 53.38% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8CC | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.02% |
| 1Y | 53.4% | -20.1% | 8.2% |
Return vs Industry: 8CC exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: 8CC exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| 8CC volatility | |
|---|---|
| 8CC Average Weekly Movement | 12.1% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8CC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8CC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 12 | Sam Lee | www.cocrystalpharma.com |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection.
Cocrystal Pharma, Inc. Fundamentals Summary
| 8CC fundamental statistics | |
|---|---|
| Market cap | €21.01m |
| Earnings (TTM) | -€17.96m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 8CC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8CC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$15.17m |
| Gross Profit | -US$15.17m |
| Other Expenses | US$3.53m |
| Earnings | -US$18.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 8CC perform over the long term?
See historical performance and comparison